patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus placebo - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.77 [0.67, 0.90]< 1 42% 21 studies (21/-) 100.0 % some concern critical moderate crucial - death or transfer to ICU 0.79 [0.50, 1.24]< 1 0% 2 studies (2/-) 84.9 % some concern not evaluable moderate crucial - deaths 0.79 [0.70, 0.90]< 1 32% 38 studies (38/-) 100.0 % some concern critical moderate crucial - deaths (time to event analysis only) 0.80 [0.65, 0.98]< 1 31% 12 studies (12/-) 98.6 % some concern low moderate crucial - clinical deterioration 0.66 [0.47, 0.93]< 1 73% 9 studies (9/-) 99.1 % low not evaluable high important - clinical improvement 1.10 [1.04, 1.17]> 1 2% 20 studies (20/-) 100.0 % some concern low moderate important - clinical improvement (14-day) 1.22 [1.07, 1.41]> 1 12% 5 studies (5/-) 99.8 % low not evaluable high important - clinical improvement (28-day) 1.47 [1.11, 1.93]> 1 0% 7 studies (7/-) 99.7 % some concern not evaluable moderate important - clinical improvement (7-day) 0.98 [0.76, 1.26]> 1 0% 2 studies (2/-) 43.1 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.08 [1.00, 1.16]> 1 0% 9 studies (9/-) 97.6 % some concern not evaluable moderate important - death or ventilation 0.72 [0.62, 0.83]< 1 0% 9 studies (9/-) 100.0 % some concern not evaluable moderate important - hospital discharge 1.13 [0.96, 1.32]> 1 36% 6 studies (6/-) 92.4 % some concern serious moderate important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 0.75 [0.59, 0.96]< 1 0% 9 studies (9/-) 99.0 % low not evaluable high important - viral clearance 1.18 [0.54, 2.54]> 1 83% 2 studies (2/-) 66.0 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.18 [0.54, 2.54]> 1 83% 2 studies (2/-) 66.0 % some concern not evaluable moderate important - ICU admission 0.56 [0.36, 0.86]< 1 0% 4 studies (4/-) 99.6 % some concern not evaluable moderate non important - recovery 1.19 [0.99, 1.42]> 1 33% 6 studies (6/-) 96.7 % low serious high non important - 00 composite safety outcome 1.56 [0.78, 3.11]< 1 0% 1 study (1/-) 10.3 % NA not evaluable important - related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - serious adverse events 0.92 [0.77, 1.10]< 1 15% 12 studies (12/-) 81.7 % some concern low moderate important - superinfection 0.74 [0.49, 1.11]< 1 57% 3 studies (3/-) 92.9 % low not evaluable high important - adverse events 1.07 [0.84, 1.38]< 1 15% 9 studies (9/-) 28.5 % some concern serious moderate non important -
LoD: level of statistical demonstration:
